The Value of
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ metabolism
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Female
Fluorodeoxyglucose F18
/ administration & dosage
Forecasting
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immunotherapy
Male
Middle Aged
Positron Emission Tomography Computed Tomography
Retrospective Studies
Survival Analysis
Advanced lung cancer
FDG PET biomarkers
Immune checkpoint inhibitor
Metabolic tumor burden
Response prediction
Journal
Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
14
01
2021
revised:
26
02
2021
accepted:
05
03
2021
pubmed:
22
4
2021
medline:
3
2
2022
entrez:
21
4
2021
Statut:
ppublish
Résumé
The objective of this study was to evaluate if In 30 patients with advanced stage IV non-small-cell lung cancer (NSCLC) and high PD-L1 expression, Median follow-up was 20 months (range, 4.2-37.6). Median PD-L1 expression was 80%. The objective response rate with RECIST 1.1 was 53.3%. Median progression-free survival (PFS) was 12.4 months (95% confidence interval [CI], 1.0-37.8), and median overall survival (OS) was 14.9 months (95% CI, 2.4-38.2). Baseline Clinical response and survival were independent from metabolic tumor volume at baseline. Reduction of metabolic tumor volume after 8 to 9 weeks of treatment was a better predictor for prolonged survival than RECIST 1.1.
Sections du résumé
BACKGROUND
The objective of this study was to evaluate if
PATIENTS AND METHODS
In 30 patients with advanced stage IV non-small-cell lung cancer (NSCLC) and high PD-L1 expression,
RESULTS
Median follow-up was 20 months (range, 4.2-37.6). Median PD-L1 expression was 80%. The objective response rate with RECIST 1.1 was 53.3%. Median progression-free survival (PFS) was 12.4 months (95% confidence interval [CI], 1.0-37.8), and median overall survival (OS) was 14.9 months (95% CI, 2.4-38.2). Baseline
CONCLUSION
Clinical response and survival were independent from metabolic tumor volume at baseline. Reduction of metabolic tumor volume after 8 to 9 weeks of treatment was a better predictor for prolonged survival than RECIST 1.1.
Identifiants
pubmed: 33879398
pii: S1525-7304(21)00053-X
doi: 10.1016/j.cllc.2021.03.001
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Immune Checkpoint Inhibitors
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
432-440Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.